Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rubicon ResearchNSE:RUBICON +1.45%18 Gross Margin % is 67.06% as of Mar. 2026, which is 1% below its 10-year median of 68.03. GuruFocus rates NSE:RUBICON with a GF Score™ of 18/100. The stock has 3 warning signs investors should review. Among 942 Drug Manufacturers companies, Rubicon Research ranks better than 79.51% on this metric.
The historical rank and industry rank for Rubicon Research's Gross Margin % or its related term are showing as below:
NSE:RUBICON'
s Gross Margin % Range Over the Past 10 Years
Min: 65.08 Med: 68.03 Max: 70.77
Current: 67.43
During the past 4 years, the highestGross Margin % of Rubicon Research was 70.77%. The lowest was 65.08%. And the median was 68.03%.
NSE:RUBICON's Gross Margin % is ranked better than 79.51% of 942
companies
in the Drug Manufacturers industry
Industry Median: 48.54
vs NSE:RUBICON: 67.43
Rubicon Research had a gross margin of 67.06% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Rubicon Research was 0.00% per year.
Rubicon Research (NSE:RUBICON) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Rubicon Research had a gross margin of 67.06% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Rubicon Research Gross Margin % Related Terms
Rubicon Research Gross Margin % Historical Data
* Premium members only.
The historical data trend for Rubicon Research's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:RUBICON vs LLY, JNJ, ABBV: Gross Margin % Comparison
For the Drug Manufacturers - General subindustry, Rubicon Research's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rubicon Research Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Rubicon Research's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Rubicon Research's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Rubicon Research (NSE:RUBICON) has a Gross Margin % of 67.06% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Rubicon Research and its competitors. This is near median its historical median of 68.03. Over the past decade, Rubicon Research's Gross Margin % has ranged from 65.08 to 70.77. According to the industry distribution chart, Rubicon Research ranks #193 out of 942 companies in the Drug Manufacturers industry, placing it in the top 20.5%.
Is Rubicon Research's Gross Margin % too high?
Rubicon Research's current Gross Margin % of 67.06% is near median its 10-year median of 68.03. Over the past 10 years, this metric has ranged from a low of 65.08 to a high of 70.77. The Drug Manufacturers industry median Gross Margin % is 48.54. Rubicon Research's value of 67.06% is 38.2% above this industry median. Based on the distribution chart, Rubicon Research ranks #193 out of 942 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Rubicon Research has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Rubicon Research's Gross Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Rubicon Research ranks #193 out of 942 companies for Gross Margin %. This places Rubicon Research in the top 21% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 48.54. Rubicon Research's value of 67.06% is 38.2% above this benchmark. Historically, Rubicon Research's own Gross Margin % has ranged from 65.08 to 70.77 over the past decade. While the company's 10-year median is 68.03 vs. the industry median of 48.54, Rubicon Research has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 942 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rubicon Research's current Gross Margin % of 67.06% is 38.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Rubicon Research and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rubicon Research's current Gross Margin % is 67.06%, which is near median its own 10-year median of 68.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rubicon Research stock overvalued right now?
Rubicon Research (NSE:RUBICON) has a current Gross Margin % of 67.06%. The current Gross Margin % is 67.06%, which is near median its 10-year median of 68.03 and 38.2% above the Drug Manufacturers industry median of 48.54. Rubicon Research's overall GF Score™ is 18/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Rubicon Research (NSE:RUBICON), the current Gross Margin % is 67.06% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rubicon Research Ltd is a pharmaceutical formulations company specializing in developing, manufacturing, and marketing branded specialty and generic prescription products. Starting as a provider of contract formulation development services, the company expanded to operate an oral solids manufacturing facility in India, offering contract development and manufacturing services for regulated markets. The company's diverse product portfolio covers multiple therapeutic areas, including analgesics and pain management, CVS, CNS, hypokalemia, skeletal muscle relaxants, NRT, gastrointestinal, metabolic, and immunosuppressants. The company operates in India, the USA, and other markets, with the majority of its revenue coming from the USA.
18GF Score
Get the complete analysis for NSE:RUBICON
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:RUBICON has been successfully added to your 
